Skip to content
Bramble

Health

Study suggests blood test could detect severe CTE in living people, but is early-stage

A JAMA study of 21 former football players found a blood biomarker, eMTBR-tau, was elevated in severe CTE confirmed after death. Researchers say the finding is preliminary and needs larger validation.

2 outlets · 1L · 0C · 1R First reported Account updated
Image: New York Post
Image: Scientific American

1 / 2

The story, neutrally told

Mixed · 2Researchers led by Boston University and Banner Health reported a blood-based method that could help identify chronic traumatic encephalopathy (CTE) in living people, a disease that can currently be confirmed only by examining brain tissue after death. Mixed · 2The study, published in the Journal of the American Medical Association on Thursday, analysed blood samples from 21 football players who donated their brains to science; 18 of them were found to have CTE at varying stages. Mixed · 2The test looks for a biomarker called endogenously cleaved microtubule-binding region tau (eMTBR-tau), which reflects tangled tau protein in the brain. Levels were significantly higher in higher-stage CTE but not in low-stage CTE or in people without CTE, so the biomarker identified the most severe cases.

Mixed · 2Because eMTBR-tau is also elevated in Alzheimer's disease, Michael Alosco, the senior author and co-director of clinical research at Boston University's CTE Center, said a second biomarker, p-tau217, which tracks closely with Alzheimer's but not CTE, could be used alongside it in a two-part test to tell the diseases apart. Some of the players had both CTE and Alzheimer's, and had the highest eMTBR-tau levels. Mixed · 2The authors stress the work is preliminary. Alosco said the team is "still in the discovery phase" with a small sample, and the test is not approved by the US Food and Drug Administration. The New York Post reports that future research will need hundreds more participants, including people at varying CTE stages and people with Alzheimer's. Mixed · 2If validated, researchers say it could open the way to clinical trials of treatments in living patients and help establish how common CTE is in the general population. There is currently no treatment for CTE, though doctors can ease symptoms.

Mixed · 2Outside experts and co-authors welcomed the result. Michael Buckland of the University of Sydney, who was not involved, called it "a watershed moment for the field" while noting there is "still a long way to go" before clinical validation. Co-author Nicholas Ashton said a blood test "has been revolutionary" for Alzheimer's and he is optimistic the same will be true for CTE. Left · 1Scientific American adds that the study came days after another JAMA paper, using mass spectrometry, found eMTBR-tau elevated in patients with severe tau-related diseases including Alzheimer's and CTE.

Every sentence links to the reporting it rests on. The pill in front of each says where its sources sit: Left, Centre or Right when one side supplies at least half of them, Mixed when they are evenly split. The number is how many outlets it cites.

Left1 outlet

Framing
Measured science report: a first-of-its-kind test that may be 'just around the corner' but depends on validation in large studies.
Emphasis
Study limits (small sample, no FDA approval), the Alzheimer's confound and the two-biomarker approach, and an independent expert's view.
Leaves out or plays down
Does not give the stage breakdown, the NFL prevalence figure or the symptom and symptom-management detail.
Charged language
“watershed moment”
For example
“A first-of-its-kind blood test for chronic traumatic encephalopathy (CTE) may be just around the corner.” — Scientific American
“given the small sample size of the study, more research is needed to confirm the findings” — Scientific American

Centre0 outlets

No centre outlet in our sources has covered this story yet.

Right1 outlet

Framing
Consumer-health angle opening on a 'game changer' for living patients and NFL players, with caveats later in the piece.
Emphasis
Prevalence among NFL players, symptoms, subgroup counts by playing level, and symptom management options.
Leaves out or plays down
Includes no independent outside expert and doesn't mention the lack of FDA approval or the p-tau217 two-part approach.
Charged language
“game changer”“groundbreaking innovation”“before it’s too late”
For example
“A simple blood test could identify CTE in living patients — a groundbreaking innovation” — New York Post
“Recent research has found that as many as 1 in 4 NFL players develop CTE” — New York Post

Ask about this story

Loading…